Systematic review of efficacy of anti–tumor necrosis factor (TNF) therapy in patients with psoriasis previously treated with a different anti–TNF agent - 17/08/16
, Robert Bissonnette, MD c, Henrique D. Teixeira, PhD, MBA d, Wendell C. Valdecantos, MD dAbstract |
Background |
Tumor necrosis factor (TNF) antagonists have improved outcomes for patients with psoriasis, but some patients are unresponsive to treatment (primary failure) or lose an initially effective response (secondary failure).
Objective |
We sought to systematically investigate the efficacy and safety of a second TNF antagonist after failure of a first TNF antagonist.
Methods |
Published primary studies evaluating the efficacy of switching TNF antagonists after failure were systematically extracted.
Results |
Fifteen studies were included. Although response rates to a second TNF antagonist were lower than for a first, a substantial proportion of patients in every study achieved treatment success. Week-24 response rates for a second antagonist were 30% to 74% for a 75% improvement in Psoriasis Area and Severity Index score and 20% to 70% for achieving a Physician Global Assessment score of 0/1; mean improvements in Dermatology Life Quality Index ranged from −3.5 to −13. In general, patients who experienced secondary failure achieved better responses than patients with primary failure. Adverse event incidences ranged from 20% to 71%, without unexpected adverse events; 0% to 11% of patients experienced serious adverse events.
Limitations |
There was no common definition of treatment failure across these studies of varied design.
Conclusions |
Some patients benefit from switching to a second TNF antagonist after failure of a first TNF antagonist, with improved quality of life.
Le texte complet de cet article est disponible en PDF.Key words : adalimumab, etanercept, failure, infliximab, psoriasis, switching, tumor necrosis factor antagonist
Abbreviations used : DLQI, PASI, PASI50, PASI75, PGA, TNF
Plan
| Literature search support was provided by Sherry Kim of AbbVie Inc. Medical writing support was provided by Katherine Groschwitz, PhD, Tiffany Brake, PhD, and Michael J. Theisen, PhD, of Complete Publication Solutions, LLC (North Wales, PA); this support was funded by AbbVie Inc. |
|
| Disclosure: Dr Yamauchi received grants and research support from, served as a consultant for, or received honoraria from AbbVie Inc, Amgen, Baxter, Celgene, Lilly ICOS LLC (now Eli Lilly), Galderma USA, Janssen-Ortho, Leo Pharma, Novartis, and Pfizer. Dr Bissonnette received grants and research support from, served as a consultant for, or received honoraria from AbbVie Inc, Amgen, Apopharma, Celgene, Dermira, Eli Lilly, Galderma, GSK-Stiefel, Incyte, Janssen, Leo Pharma, Merck, Novartis, Pfizer, Tribute, and Xenoport. Drs Teixeira and Valdecantos are employees of AbbVie Inc and may own AbbVie Inc stock and/or stock options. |
Vol 75 - N° 3
P. 612 - septembre 2016 Retour au numéro
Article précédent
- All hairstyles are not created equal: What the dermatologist needs to know about black hairstyling practices and the risk of traction alopecia (TA)
- Alessandra Haskin, Crystal Aguh
- Gabapentin and pregabalin for the treatment of chronic pruritus
- Kazuki M. Matsuda, Divya Sharma, Ariel R. Schonfeld, Shawn G. Kwatra
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?